Triple Agonist Reduces Hemoglobin A 1C and Weight in Patients With Type 2 Diabetes
The first-in-class glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 receptor (GLP-1), and glucagon triple hormone receptor retatrutide lowered hemoglobin A1C (HBA1c) levels and weight in patients with type 2 diabetes, according to topline results from a phase 3 clinical trial.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.